RxDoctor Payments Data

Sean Marvil, MD

Orthopaedic Surgery · Taos, NMNPI 1891924668

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Arthrex at 40.7% of the total. Reporting peaked in 2019 at $2,639 and has fallen 80.7% since, to $509 in 2025.

$8,579in general payments, 2019–2025

Across 92 payments — averaging $93.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$3K
  • Medacta USA, Inc.$1K
  • Smith+Nephew$870
  • Stryker$846
  • FX Shoulder Solutions, Inc$669
  • Gemini Mountain Medical, LLC$460
  • plus $928 from 8 others

What the payments were for

  • Travel & lodging$1,31915%
  • Food & beverage$4,59154%
  • Education$2,67031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,579 in reported general payments places this provider in the 70th percentile of 107 orthopaedic surgery providers in New Mexico.

See all orthopaedic surgery providers in New Mexico

Medicare billing

Part B allowed, 2024
$240,069
Medicare patients
626
Services billed
9,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clindamycin Phosphate69$1,365
Celecoxib53$1,041
Mupirocin72$596
Amoxicillin12$30

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Taos

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →